Remedy Plan Therapeutics, a Gaithersburg, Maryland-based clinical-stage biotech, announced multiple development and corporate milestones on September 15, 2026 for RPT1G, its first-in-class hyperbolic NAMPT inhibitor: patients in Cohort 1 of its Phase 1 trial completed a full 28-day treatment cycle, Cohort 2 enrollment has begun, and the FDA has accepted an IND application to study RPT1G in solid tumors.
Founder and CEO Greg Crimmins, PhD, called the Cohort 1 result a scientific first: “Our progress to date in this trial marks the first time that therapeutic NAMPT inhibition, without limiting toxicity, has been successfully achieved in patients with cancer for longer than just a few days. This represents a significant scientific advancement that had previously been considered impossible to accomplish.”
Solving NAMPT Inhibition’s Toxicity Problem
RPT1G is designed to selectively target cancer cell metabolism through a hyperbolic inhibition mechanism, controlling NAMPT enzyme activity rather than shutting it down completely, an approach meant to preserve metabolic function in healthy cells while disrupting it in cancer cells and sidestepping the on-target toxicities that have historically limited NAMPT inhibitors. The drug is being evaluated in a multi-center, open-label, dose-escalation Phase 1 trial (NCT07107126) using a traditional 3+3 design with optional cohort expansion, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes; the release doesn’t disclose specific safety, tolerability, or efficacy data from Cohort 1 beyond the completed treatment cycle. The newly accepted IND extends RPT1G’s potential reach into solid tumors alongside its current hematologic focus.
New Financing and a New Clinical Development Lead
Remedy Plan also closed a roughly $30 million Series A extension led by Schooner Capital and existing investors, and appointed Dr. Oleg Zernovak as Vice President of Clinical Development. Zernovak brings more than 20 years of drug development experience, most recently as Executive Director of Hematology Clinical Development at BeOne Medicines, with prior roles at Curis, Cellectis, Janssen, Daiichi-Sankyo, Celgene, and Novartis Oncology, including direct experience managing AML and MDS trials.
Crimmins tied the two moves together: “Oleg’s expertise in hematologic malignancies, with direct experience managing clinical trials in AML and MDS, will be deeply valuable as we advance RPT1G and expand our emerging pipeline of first-in-class NAMPT inhibitors. Meanwhile, the closing of our Series A extension directly supports our ability to generate deeper and strategically actionable data from the ongoing Phase 1 trial during this upcoming year of growth for our company.”
About Remedy Plan Therapeutics
Remedy Plan Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies that target fundamental metabolic vulnerabilities in disease. The company’s proprietary drug discovery platform has enabled the development of a new class of novel NAMPT inhibitors designed to overcome decades-long challenges associated with targeting this pathway. Remedy Plan’s lead candidate, RPT1G, is currently being evaluated in an ongoing Phase 1 clinical study in patients with relapsed/refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS) (NCT07107126). In parallel, the company is advancing clinical studies that explore NAMPT inhibition across additional oncology applications, as well as autoimmune and metabolic diseases.
